Effectiveness of co-oximetry and minimum advice for smoking cessation in kidney transplant recipients

ISRCTN ISRCTN16615772
DOI https://doi.org/10.1186/ISRCTN16615772
Secondary identifying numbers N/A
Submission date
05/06/2015
Registration date
02/07/2015
Last edited
17/08/2023
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Mental and Behavioural Disorders
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English Summary

Background and study aims
In order to modify a problem behaviour, for example smoking, over-eating or drinking too much, a person has to be motivated to make that change. Many people are in denial of their problem behaviour and may not see their behaviour as problematic; these people are considered to be in the precontemplation stage. In contrast, some people are willing to admit that they may have a problem, are comtemplating changing their behaviour but are ambivalent about doing so. Here, we are looking at how successful measuring exhaled carbon monoxide (MO) along with brief advice for smoking cessation helps smoking kidney recipients to stop smoking, increase their motivation to stop smoking or reduce the number of cigarettes that they smoke per day. We will be comparing the results of this intervention for people at the contemplation stage compared with the precontemplation stage of change. We will also be looking at how well it works compared to when people are given brief advice alone.

Who can participate?
Smoking kidney transplant recipients who are prepared to give up smoking, are contemplating it or are in the precontemplation stage.

What does the study involve?
Participants are randomised into one of two groups. Those in group 1 are assigned as controls. Those in group 2 are assigned to the intervention group. All participants are given a brief advisory session about giving up smoking; this is individually tailored and provides information about the health risks of smoking and the main advantages of quitting the habit. Participants in the intervention group also have the oxygen carrying state of their haemoglobin (protein in red blood cells that carry oxygen) measured using a CO-oximeter; this detects the amount of carbon monoxide (CO) that the participant has in their body. All participants from both groups are followed up 3 months, 6 months and 9 months later. At each of these visits, the anti-smoking advice is repeated for the control group and anti-smoking advice plus CO-oximetry for the intervention group. How well the intervention performs is assessed at 3, 6, 9 and 12 months. This includes looking at how many participants have reduced the amount of cigarettes they smoke, or stop smoking altogether.

What are the possible benefits and risks of participating?
Not provided at time of registration

Where is the study run from?
University Hospital Complex A Coruña (Spain)

When is the study starting and how long is it expected to run for?
December 2012 to December 2015

Who is funding the study?
Instituto de Salud (National Institute of Health) Carlos III (Spain)

Who is the main contact?
Dr Salvador Pita- Fernández

Contact information

Dr Salvador Pita-Fernández
Scientific

Complejo Hospitalario Universitario de A Coruña
Clinical epidemiology and biostatistics Unit
As Xubias de Arriba 84
A Coruña
15006
Spain

Study information

Study designRandomized controlled trial (open, with blinded evaluation)
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Hospital
Study typePrevention
Participant information sheet Not available in web format, please use contact details to request a participant information sheet
Scientific titleEffectiveness of co-oximetry and minimum advice for smoking cessation in kidney transplant recipients: a randomized controlled trial
Study hypothesisTo compare, in smoking kidney transplant recipients in the contemplation or precontemplation stage of change, the effectiveness of the measurement of exhaled carbon monoxide (CO) plus brief advice for smoking cessation, compared with brief advice alone, with respect to:
1. Smoking cessation
2. Increased motivation to quit smoking
3. Reduction in the number of cigarettes smoked per day
Ethics approval(s)Comité ético de investigación clínica de Galicia, ref: 2011/061
ConditionSmoking in kidney transplant recipients
InterventionPatients will be randomized to:
1. The control group (brief advice for smoking cessation)
or
2. Intervention (brief advice + exhaled CO measurement)
Intervention typeBehavioural
Primary outcome measureThe effectiveness will be evaluated at 6 and 12 months by smoking cessation confirmed by nicotine test results.
Secondary outcome measuresAbandoned self-declared (by number of cigarettes smoked per day and changes in the dependency stage).
Overall study start date01/12/2012
Overall study end date31/12/2015

Eligibility

Participant type(s)Patient
Age groupAdult
SexBoth
Target number of participantsn= 122 (alfa=95%, Power=80% Loss=10%.Difference to detect 12%)
Total final enrolment122
Participant inclusion criteriaSmoking kidney transplant recipients, in preparation stage, precontemplation and contemplation stage of change, that give their consent to participate
Participant exclusion criteriaPatients with terminal illness or mental disability.
Recruitment start date01/12/2012
Recruitment end date31/12/2015

Locations

Countries of recruitment

  • Spain

Study participating centre

University Hospital Complex A Coruña (Sergas Complejo Hospitalario Universitario de A Coruña)
As Xubias de Arriba 84
A Coruña
15006
Spain

Sponsor information

Complejo Hsopitalario Universitario de A Coruña
Hospital/treatment centre

As Xubias de Arriba 84
A Coruña
15006
Spain

ROR logo "ROR" https://ror.org/044knj408

Funders

Funder type

Government

Instituto de Salud Carlos III
Government organisation / National government
Alternative name(s)
SaludISCIII, InstitutodeSaludCarlosIII, Instituto de Salud Carlos III | Madrid, Spain, Carlos III Institute of Health, Institute of Health Carlos III, Carlos III Health Institute, ISCIII
Location
Spain

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot expected to be made available
Publication and dissemination plan
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Protocol article protocol 01/04/2016 Yes No
Results article 23/09/2020 17/08/2023 Yes No

Editorial Notes

17/08/2023: Publication reference and total final enrolment added.
04/04/2016: Publication reference added.